Yamagata University · Faculty of Medicine

Research keywordsglioma stem cells・MDM4 inhibitor CEP-1347・p53 activation・HDAC class I inhibitor・Bcl-xL inhibition・TERT promoter mutation・glioblastoma・malignant brain tumors・temozolomide sensitization・MKK4 7 inhibitor

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• HDAC Class I Inhibitor Domatinostat Induces Apoptosis Preferentially in Glioma Stem Cells Through p53-Dependent and -Independent Activation of BAX Expression，International Journal of Molecular Sciences，26(16) 7803，2025年08月2025 · Yurika Nakagawa-Saito , Yasufumi Ito , Kazuki Nakamura , Yuta Mitobe , Keita Togashi ,Shuhei Suzuki , Senri Takenouchi , Asuka Sugai , Yukihiko Sonoda , Chifumi Kitanaka , Masashi Okada
• Effective Targeting of Glioma Stem Cells by BSJ-04-122, a Novel Covalent MKK4/7 Dual Inhibitor，Anticancer Research，45(7) 2917-2924，2025年07月2025 · Kazuki Nakamura，Yasufumi Ito , Senri Takenouchi , Yurika Nakagawa-Saito , Shuhei Suzuki ， Keita Togashi , Asuka Sugai , Yuta Mitobe , Yukihiko Sonoda , Chifumi Kitanaka , Masashi Okada
• Targeting Bcl-xL with Navitoclax Effectively Eliminates Senescent Tumor Cells That Appear Following CEP-1347-Induced Differentiation of Glioma Stem Cells，International Journal of Molecular Sciences，26(14) 6984，2025年07月2025 · Senri Takenouchi , Yasufumi Ito , Kazuki Nakamura , Yurika Nakagawa-Saito , Yuta Mitobe , Keita Togashi , Shuhei Suzuki , Asuka Sugai , Yukihiko Sonoda , Chifumi Kitanaka , Masashi Okada
• Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group，Jpn J Clin Oncol，2024年10月2024 · Kazuya Motomura, Keita Sasaki,....,Mitobe Y,....他

• 基盤研究(C)，2024年04月 ～ 2027年03月，グリオーマ幹細胞の物理的・機能的消去を同時に狙う独自戦略に基づく新規治療法開 発2024

• Official profile